neoantigen complex peptide loaded dendritic cells

Neoantigen complex peptide loaded dendritic cells are a form of personalized cancer immunotherapy in which dendritic cells (DCs) derived from a patient's peripheral blood are loaded ex vivo with synthetic peptides corresponding to tumor-specific neoantigens. These neoantigens are unique peptides generated by non-synonymous somatic mutations present only in the patient’s tumor and absent from normal tissues. The process involves sequencing the patient’s tumor and normal tissue to identify candidate immunogenic neoantigens, synthesizing these peptides, and then pulsing autologous monocyte-derived DCs with them. The resulting cell product is administered back to the patient—often via intranodal injection—to prime T-cell responses specifically against cancer cells expressing those mutated antigens. This approach aims to elicit robust and specific anti-tumor immune responses while sparing healthy tissue. Early clinical studies have shown safety and some evidence of efficacy in advanced cancers resistant to standard therapies[2][3]. This therapy is highly individualized; each batch is custom-made for each patient based on their unique tumor mutation profile.

Other names

neoantigen peptide-pulsed dendritic cellsneoantigen-pulsed DC vaccinepersonalized neoantigen-pulsed DC vaccine